Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells $164,495.64 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey Flier sold 3,053 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the transaction, the director directly owned 27,856 shares of the company’s stock, valued at approximately $1,500,881.28. This represents a 9.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

Shares of SRRK opened at $56.03 on Thursday. The firm has a market capitalization of $6.71 billion, a PE ratio of -15.61 and a beta of 0.67. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $57.80. The company’s fifty day moving average price is $48.99 and its 200-day moving average price is $46.85.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the prior year, the firm posted ($0.67) earnings per share. On average, equities research analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Institutional Trading of Scholar Rock

Several hedge funds and other institutional investors have recently bought and sold shares of SRRK. AQR Capital Management LLC lifted its holdings in Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after acquiring an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the period. Millennium Management LLC increased its holdings in shares of Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after purchasing an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after purchasing an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Scholar Rock in the 1st quarter valued at $77,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SRRK. Wedbush raised their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 1st. HC Wainwright increased their price target on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Barclays upped their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).